Literature DB >> 23279347

Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies.

Dario Cocito, Grazia Serra, Ilaria Paolasso, Diego A Barilà, Leonardo Lopiano, Luigi Cattel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23279347     DOI： 10.1111/j.1529-8027.2012.00444.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN： 1085-9489            Impact factor:   3.494


× No keyword cloud information.
  10 in total

Review 1.  Update on therapy of chronic immune-mediated neuropathies.

Authors:  Chiara Briani; Dario Cocito; Marta Campagnolo; Pietro Emiliano Doneddu; Eduardo Nobile-Orazio
Journal:  Neurol Sci       Date:  2021-01-16       Impact factor: 3.307

Review 2.  Multifocal motor neuropathy: current therapies and novel strategies.

Authors:  Eduardo Nobile-Orazio; Francesca Gallia
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546

3.  Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study.

Authors:  Dario Cocito; Aristide Merola; Erdita Peci; Anna Mazzeo; Raffaella Fazio; Ada Francia; Paola Valentino; Rocco Liguori; Massimiliano Filosto; Gabriele Siciliano; Angelo Maurizio Clerici; Stefania Lelli; Girolama Alessandra Marfia; Giovanni Antonini; Ilaria Cecconi; Eduardo Nobile-Orazio; Leonardo Lopiano
Journal:  J Neurol       Date:  2014-08-23       Impact factor: 4.849

4.  Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.

Authors:  Eugenia Piscitelli; Marida Massa; Bernardo Maria De Martino; Carmela Simona Serio; Gaspare Guglielmi; Giovanni Colacicco; Francesco Tuccillo; Francesco Habetswallner
Journal:  Eur J Hosp Pharm       Date:  2020-10-29

5.  Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.

Authors:  Carlo Lazzaro; Leonardo Lopiano; Dario Cocito
Journal:  Neurol Sci       Date:  2014-01-28       Impact factor: 3.307

6.  Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.

Authors:  Clemence Perraudin; Aline Bourdin; Francois Spertini; Jérôme Berger; Olivier Bugnon
Journal:  J Clin Immunol       Date:  2016-05-02       Impact factor: 8.317

7.  Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis.

Authors:  Clémence Perraudin; Aline Bourdin; Alex Vicino; Thierry Kuntzer; Olivier Bugnon; Jérôme Berger
Journal:  PLoS One       Date:  2020-11-25       Impact factor: 3.240

Review 8.  Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.

Authors:  Paolo Ripellino; Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Autoimmune Dis       Date:  2014-01-14

9.  Home versus hospital immunoglobulin treatment for autoimmune neuropathies: A cost minimization analysis.

Authors:  Gwendal Le Masson; Guilhem Solé; Claude Desnuelle; Emilien Delmont; Marc Gauthier-Darnis; Sophie Puget; Isabelle Durand-Zaleski
Journal:  Brain Behav       Date:  2018-01-26       Impact factor: 2.708

10.  Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy.

Authors:  Ingrid J T Herraets; Jaap N E Bakers; Ruben P A van Eijk; H Stephan Goedee; W Ludo van der Pol; Leonard H van den Berg
Journal:  J Neurol       Date:  2019-07-19       Impact factor: 4.849
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.